

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/550,165
(use as many sheets as necessary)		<b>Filing Date</b>	July 21, 2006
Sheet 1 of 1		<b>First named Inventor</b>	Paul B. Savage
		<b>Group Art Unit</b>	1623
		<b>Examiner name</b>	Ganapathy Krishnan
		<b>Attorney Docket Number</b>	017968-9010 US00

**U.S. Patent Documents**

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
/G.K.	5,767,092	Koezuka et al.	6/16/1998
	6,531,453	Taniguchi et al.	3/11/2003
	6,747,010	Taniguchi et al.	6/8/2004
	2002/0115624	Behar et al.	8/22/2002
	2003/0139351	Yagita	8/14/2003
	2003/0153514	Yagita	8/14/2003
	2004/0266726	Yagita	12/30/2004
	2006/0073118	Bendelac et al.	4/6/2006
	2008/0095787	Teyton	4/24/2008
/G.K.	11/814103	Teyton et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
/G.K.	WO	2005/000348	ISIS Innovation et al.	1/6/2005		
	WO	2006/083671	Brigham Young University et al.	8/10/2006		
	WO	2007/118234	The Scripps Research Institute et al.	10/18/2007		
/G.K.	WO	2008/005824	The Scripps Research Institute et al.	1/10/2008		

Examiner Signature	/Ganapathy Krishnan/	Date Considered	09/09/2009
--------------------	----------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/550,165
Sheet	1	of	4	Filing Date	July 21, 2006
				First Named Inventor	Paul B. Savage
				Group Art Unit	1623
				Examiner Name	Ganapathy Krishnan
				Attorney Docket Number	017968-9010 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.		
/G.K./	ANDO, H. et al., "Solid-phase capture-release strategy applied to oligosaccharide synthesis on a soluble polymer support," <i>Angew. Chem. Int. Ed.</i> (2001) 40:4725-4728		
	BENDELAC, A. et al., "Increased interleukin 4 and immunoglobulin E production in transgenic mice overexpressing NK1 T cells," <i>J. Exp. Med.</i> (1996) 184:1285-1293		
	BRIGL, M. et al., "CD1: T cell function and antigen presentation," <i>Annu. Rev. Immunol.</i> (2004) 22:817-890		
	BRIGL, M. et al., "Mechanism of CD1d-restricted natural killer T cell activation during microbial infection," <i>Nat. Immunol.</i> (2003) 4:1230-1237		
	CANTU, C. et al., "The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs," <i>J. Immunol.</i> (2003) 170:4673-4682		
	FUJII, S-I. et al., "Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein," <i>J. Exp. Med.</i> (2003) 198:267-279		
	GARRITY, G.M. et al., <i>Taxonomic Outline of the Prokaryotic Genera</i> , Bergey's Manual of Systematic Bacteriology, 2nd Edition (April 2001)		
	GODFREY, D.I. et al., "Going both ways: immune regulation via CD1d-dependent NKT cells," <i>J. Clin. Invest.</i> (2004) 114(10):1379-1388		
/G.K./	GODFREY, D.I. et al., "The elusive NKT cell antigen - is the search over?" <i>Science</i> (2004) 306:1687-1688		

Examiner Signature	/Ganapathy Krishnan/	Date Considered	09/09/2009
--------------------	----------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Application Number</b>	10/550,165
Sheet	2	of	4	<b>Filing Date</b>	July 21, 2006
				<b>First Named Inventor</b>	Paul B. Savage
				<b>Group Art Unit</b>	1623
				<b>Examiner Name</b>	Ganapathy Krishnan
				<b>Attorney Docket Number</b>	017968-9010 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.				
/G.K./	GOFF, R.D. et al., "Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells," J. Am. Chem. Soc. (2004) 126:13602-13603				
	GUI, M. et al., "TCR beta chain influences but does not solely control autoreactivity of V alpha 14J28IT cells," J. Immunol. (2001) 167(11):6239-6246				
	GUMPERZ, J.E. et al., "Functional distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining," J. Exp. Med. (2002) 195(5):625-636				
	HERMANS, I.F. et al., "NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells," J. Immunol. (2003) 171:5140-5147				
	IIDA, N. et al., "A sulfated glucosylceramide from rat kidney," J. Biol. Chem. (1989) 264(10):5974-5980				
	ISMAIL, N. et al., "Overproduction of TNF-alpha b CD8+ type 1 cells and down-regulation of IFN- $\gamma$ production by CD4+ Th1 cells contribute to toxic shock-like syndrome in an animal model of fatal monocytotropic ehrlichiosis," J. Immunol. (2004) 172:1786-1800				
	KARADIMITRIS, A. et al., "Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography," Proc. Natl. Acad. Sci. USA (2001) 98(6):3294-3298				
	KINJO, Y. et al., "Recognition of bacterial glycosphingolipids by natural killer T cells," Nature (2005) 434:520-525				
/G.K./	KRONENBERG, M. "Toward an understanding of NKT cell biology: progress and paradoxes," Ann. Rev. Immunol. (2005) 23:877-900				

Examiner Signature	/Ganapathy Krishnan/	Date Considered	09/09/2009
--------------------	----------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/550,165
Sheet	3	of	4	Filing Date	July 21, 2006
				First Named Inventor	Paul B. Savage
				Group Art Unit	1623
				Examiner Name	Ganapathy Krishnan
				Attorney Docket Number	017968-9010 US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.			
/G.K./		LEE, P.T. et al., "Testing the NKT cell hypothesis on human IDDM pathogenesis," <i>J. Clin. Invest.</i> (2002) 110(6):793-800			
		MATTNER, J. et al., "Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections," <i>Nature</i> (2005) 434:525-529			
		MATSDUDA, J.L. et al., "Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers," <i>J. Exp. Med.</i> (2000) 192(5):741-753			
		PETROVSKY, N. et al., "Vaccine adjuvants: current state and future trends," <i>Immunol. Cell Biol.</i> (2004) 82:488-496			
		ROCK, K.L. et al., "Natural endogenous adjuvants," <i>Springer Semin. Immunopathol.</i> (2005) 26:231-246			
		SIDOBRE, S. et al., "CD1d tetramers: a powerful tool for the analysis of glycolipid reactive T cells," <i>J. Immunol. Methods</i> (2002) 268:107-121			
		VAN KAER, L., "Alpha-galactosylceramide therapy for autoimmune diseases: prospects and obstacles," <i>Nat. Rev. Immunol.</i> (2005) 5:31-42			
		WU et al., "Bacterial glycolipids and analogs as antigen for CD1d-restricted NKT cells," <i>PNAS</i> (2005) 102(5):1351-1356			
/G.K./		ZAJONC, D.M. et al., "Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor," <i>Nat. Immunol.</i> (2005) 6:810-818			

Examiner Signature	/Ganapathy Krishnan/	Date Considered	09/09/2009
--------------------	----------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/550,165
				Filing Date	July 21, 2006
				First Named Inventor	Paul B. Savage
				Group Art Unit	1623
				Examiner Name	Ganapathy Krishnan
Sheet	4	of	4	Attorney Docket Number	
				017968-9010 US00	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
/G.K./	ZHOU, D. et al., "Lysosomal glycosphingolipid recognition by NKT cells," Science (2004) 306:1786-1789
	International Search Report and Written Opinion of International Searching Authority of PCT/US2007/072451 dated November 27, 2007
	International Search Report and Written Opinion of International Searching Authority of PCT/US06/002781 dated December 20, 2006
	Supplementary Search Report of the European Patent Office for Application No. 03816701.1 dated September 17, 2007
	European Office Action for Application No. 03816701.1 dated November 29, 2007
	Written Opinion of International Preliminary Examining Authority for International Application No. PCT/US03/08530 dated June 30, 2005
	International Search Report of International Searching Authority for Application No. PCT/US03/08530 dated August 3, 2004
/G.K./	International Search Report and Written Opinion of International Searching Authority for International Application No. PCT/US07/66250 dated October 15, 2007

Examiner Signature	/Ganapathy Krishnan/	Date Considered	09/09/2009
--------------------	----------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.